标题：参附注射液辅助治疗脓毒症的效果及对患者血清PCT、hs-CRP及免疫指标的影响

      作者：徐瑞华 1，张会珍 2，张娆娆 1    1.郑州大学第五附属医院重症医学科，河南 郑州 450000；2.合肥市滨湖医院，安徽 合肥 230000

      卷次： 2022年33卷1期

      【摘要】 目的 观察参附注射液辅助治疗脓毒症患者的效果，并探讨其对患者血清降钙素原(PCT)、超敏C反应蛋白(hs-CRP)及免疫指标的影响。方法 回顾性分析2019年4月至2021年4月于郑州大学第五附属医院重症医学科和合肥市滨湖医院住院治疗的 68例脓毒症患者的临床资料，依据治疗方案将其分为观察组和对照组各 34例。对照组患者在常规治疗的基础上给予氢化可的松静脉注射治疗，观察组在对照组治疗的基础上联合参附注射液静脉滴注治疗，均连续用药一周。比较两组患者的临床疗效、治疗前、治疗 1周后的白细胞计数(WBC)、PCT、hs-CRP、T淋巴细胞亚群(CD4+、CD8+、CD4+/CD8+、CD14+/HLA-DR)和序贯器官衰竭评分(SOFA)、急性生理学和慢性健康评分(APACHEⅡ)。结果 观察组患者的临床治疗总有效率为82.35%，明显高于对照组的58.82%，差异有统计学意义(P<0.05)；治疗后，观察组患者的WBC、PCT、hs-CRP水平和SOFA、APACHEⅡ评分明显低于对照组，CD14+/HLA-DR明显高于对照组，差异均有统计学意义(P<0.05)。结论 参附注射液辅助治疗可有效调节脓毒症患者机体炎症指标和免疫指标水平，改善患者SOFA和APACHEⅡ评分，临床治疗效果显著。
      【关键词】 脓毒症；参附注射液；治疗效果；炎症指标；免疫指标
      【中图分类号】 R631 【文献标识码】 A 【文章编号】 1003—6350（2022）01—0010—04

Effect of Shenfu injection in the adjuvant treatment of patients with sepsis and its effect on serum procalcitonin,hs-CRP and immune indexes.
XU Rui-hua 1, ZHANG Hui-zhen 2, ZHANG Rao-rao 1. 1. Intensive Care Unit, the FifthAffiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan, CHINA; 2. Hefei Binhu Hospital, Hefei 230000,Anhui, CHINA
【Abstract】 Objective To observe the effect of Shenfu injection in the adjuvant treatment of sepsis patients,and to explore the effects of serum procalcitonin (PCT), hs-CRP and immune indexes. Methods The clinical data of 68patients with sepsis hospitalized in the Intensive Care Unit of the Fifth Affiliated Hospital of Zhengzhou University andHefei Binhu Hospital from April 2019 to April 2021 were retrospectively analyzed. They were divided into an observa-tion group and a control group, with 34 patients in each group according to the treatment plan. The control group wasgiven hydrocortisone intravenous infusion on the basis of conventional treatment, while the observation group was givenshenfu injection intravenous infusion on the basis of the treatment of the control group, continuously for one week. Theclinical efficacy, white blood cell count (WBC), PCT, hs-CRP, T lymphocyte subsets (CD4+, CD8+, CD4+/CD8+, CD14+/HLA-DR), sequential organ failure score (SOFA), acute physiology and chronic health score (APACHEⅡ) were com-pared between the two groups before treatment and 1 week after treatment. Results The total effective rate of the obser-vation group was 82.35%, which was significantly higher than 58.82% of the control group (P<0.05). After treatment,the levels of WBC, PCT, hs-CRP, SOFA, and APACHEⅡ scores in the observation group were significantly lower thanthose in control group, while the levels of CD14+/HLA-DR were significantly higher than those in control group, withstatistically significant differences (P<0.05). Conclusion Shenfu injection adjuvant therapy can effectively regulate thelevels of inflammatory and immune indexes in patients with sepsis, improve the SOFA and APACHE Ⅱ scores, and theclinical treatment effect is significant.
      【Key words】 Sepsis; Shenfu injection; Therapeutic effect; Inflammatory indicators; Immune indexes